Stefan Bordonaro
Healthcare, biotechnology, mid-cap, small-cap

Akorn Inc: Growing Under The Radar

The basis of this article is to provide:

1. A brief overview of about Akorn Inc.

2. An analysis of Akorn's core business

3. Evaluation of sales, market/sector, and financials (2013 Q1 and Q2)

4. Opinionated conclusions and price targets

Akorn Inc. (NASDAQ: AKRX)

Executive Summary:

Akorn Inc. ("Akorn," "AKRX" or the "Company") is a generic pharmaceutical company with a market cap of roughly $1.6 billion (at time of writing). A quick analysis of Akorn reveals that the company has experienced substantial revenue growth over the past three years. Subsequently, Akorn has increased its share price from the $1.80 range to the $16 range (a total return of roughly 789%). Despite the significant increase in valuation, Akorn still remains

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details